Starting & Staying on Treatment, Made Easy

*CIMplicity^® Savings
CIMplicity^® Savings (the "Program") provides CIMZIA^® (certolizumab pegol) Prefilled Syringe or Lyophilized Powder to eligible patients for as little as $0 per dose. Eligible patients must have commercial insurance coverage and a valid prescription for CIMZIA Prefilled Syringe or Lyophilized Powder consistent with FDA-approved product labeling. The Program is not valid (1) for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded healthcare programs (including but not limited to any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient's commercial insurance plan reimburses for the entire cost of the drug, (3) for uninsured or cash paying patients, (4) where the product is not covered by patient's insurance, or (5) where otherwise prohibited by law. Product shall be dispensed pursuant to Program rules and federal and state laws. The value of the Program is exclusively for the benefit of patients and is intended to be credited in full toward patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance and deductibles. Patient may not seek reimbursement for the value received from this Program from other parties, including any health insurance program or plan, government healthcare program, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the U.S. and Puerto Rico. This Program is not health insurance. Proof of purchase may be required. This Program is not transferrable and cannot be combined with any other savings, free trial, or similar offer. UCB, Inc. reserves the right to amend or end this Program at any time without notice. Subject to the prior sentence, this Program expires at 11:59 p.m. on December 31. Patients that meet the above requirements may re-enroll in the Program each year.

CIMplicity^® Administration Savings Program
The CIMplicity^® Administration Savings Program (the "Program") provides eligible patients with reimbursement for in-office administration-related costs (subject to an annual cap) for CIMZIA^® (certolizumab pegol) Lyophilized Powder, subject to submission of an Explanation of Benefits (EOB) form to CIMplicity. Eligible patients must have commercial insurance coverage and a valid prescription for CIMZIA Lyophilized Powder consistent with FDA­-approved product labeling. The total patient out-of-pocket cost under the Program is dependent on the patient's health insurance plan. The Program assists with costs related to the administration of CIMZIA Lyophilized Powder only. The Program does not assist with the cost of other administrations, medications, procedures, or office visit fees. After reaching the maximum Program's benefit amounts, the patient will be responsible for all remaining out-of-pocket expenses. The Program's benefit amounts cannot exceed the patient's out-of-pocket expenses for administration of CIMZIA Lyophilized Powder. The Program is not valid (1) for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded healthcare programs (including but not limited to any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient's commercial insurance plan reimburses for the entire cost of the drug, (3) for uninsured or cash paying patients, (4) where the product is not covered by patient's insurance, or (5) where otherwise prohibited by law. Product shall be dispensed pursuant to Program rules and federal and state laws. The value of the Program is exclusively for the benefit of patients and is intended to be credited in full toward patient out-of-pocket obligations and maximums, including applicable co­payments, coinsurance, and deductibles. Patient may not seek reimbursement for the value received from this Program from other parties, including any health insurance program or plan, government healthcare program, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the U.S. and Puerto Rico. This Program is not health insurance. This Program is not transferrable and cannot be combined with any other savings, free trial, or similar offer. UCB, Inc. reserves the right to amend or end this Program at any time without notice. Subject to the prior sentence, this Program expires at 11:59 p.m. on December 31. Patients that meet the above requirements may re-enroll in the Program each year.

CIMplicity^® Covered
Eligible, commercially insured patients who are enrolled in CIMplicity Covered^® (the "Program") on or before December 31, 2024 may continue to participate in the Program, subject to the below continued eligibility requirements and terms and conditions. The Program provides CIMZIA^® (certolizumab pegol) Prefilled Syringe to eligible patients for $0 per dose for up to two (2) years or until the patient’s commercial insurance plan makes a final determination of coverage (i.e., either approves coverage or issues a final denial of coverage for the drug), whichever occurs earlier. Eligible patients must have commercial insurance, a valid prescription for CIMZIA Prefilled Syringe consistent with FDA-approved product labeling, and a denial of insurance coverage based on documented submission of a prior authorization request. To maintain eligibility in the Program, an appeal of the coverage denial (or documentation as may otherwise be required by the payer) must be submitted within sixty (60) days following the prior authorization denial. Program is not available (1) to patients whose prescriptions are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, or any other federal- or state-funded health care programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), (2) where a patient’s insurance covers the drug, (3) to uninsured or cash-paying patients, or (4) where otherwise prohibited by law. Product shall be dispensed pursuant to Program rules and federal and state laws. Patients may be asked to re-verify insurance coverage status during participation in the Program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. This Program is not transferrable and cannot be combined with any other savings, free trial, or similar offer for the specified prescription. The patient, or healthcare provider on the patient’s behalf, must not submit any claim for reimbursement for product provided under this Program to any third-party payer. UCB, Inc. reserves the right to end or amend this Program without notice.

^‡Nurse Navigators do not provide medical advice and will refer you to your healthcare professional for any treatment-related questions.

If you are uninsured, other financial assistance may be available. Call UCBCares^® toll free at 1-844-599-CARE (2273) for more information. Some program and eligibility restrictions apply. Please consult your doctor if you have any questions about your condition or treatment. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

UCB, Inc., is not liable for unintended or unauthorized use of the CIMplicity Savings Card if it is lost or stolen.